1. Home
  2. FSK vs BLCO Comparison

FSK vs BLCO Comparison

Compare FSK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSK
  • BLCO
  • Stock Information
  • Founded
  • FSK 2007
  • BLCO 1853
  • Country
  • FSK United States
  • BLCO Canada
  • Employees
  • FSK N/A
  • BLCO N/A
  • Industry
  • FSK Investment Managers
  • BLCO Ophthalmic Goods
  • Sector
  • FSK Finance
  • BLCO Health Care
  • Exchange
  • FSK Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • FSK 6.0B
  • BLCO 6.3B
  • IPO Year
  • FSK N/A
  • BLCO 2022
  • Fundamental
  • Price
  • FSK $22.47
  • BLCO $17.17
  • Analyst Decision
  • FSK Hold
  • BLCO Buy
  • Analyst Count
  • FSK 8
  • BLCO 12
  • Target Price
  • FSK $20.19
  • BLCO $20.73
  • AVG Volume (30 Days)
  • FSK 1.2M
  • BLCO 396.1K
  • Earning Date
  • FSK 02-24-2025
  • BLCO 02-19-2025
  • Dividend Yield
  • FSK 12.50%
  • BLCO N/A
  • EPS Growth
  • FSK N/A
  • BLCO N/A
  • EPS
  • FSK 1.89
  • BLCO N/A
  • Revenue
  • FSK $1,761,000,000.00
  • BLCO $4,684,000,000.00
  • Revenue This Year
  • FSK N/A
  • BLCO $17.32
  • Revenue Next Year
  • FSK N/A
  • BLCO $5.98
  • P/E Ratio
  • FSK $11.92
  • BLCO N/A
  • Revenue Growth
  • FSK N/A
  • BLCO 18.01
  • 52 Week Low
  • FSK $18.31
  • BLCO $13.16
  • 52 Week High
  • FSK $22.42
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • FSK 68.02
  • BLCO 35.11
  • Support Level
  • FSK $21.04
  • BLCO $17.00
  • Resistance Level
  • FSK $22.17
  • BLCO $17.57
  • Average True Range (ATR)
  • FSK 0.28
  • BLCO 0.45
  • MACD
  • FSK 0.07
  • BLCO -0.00
  • Stochastic Oscillator
  • FSK 100.00
  • BLCO 22.80

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: